Law firm Schall announces filing of class action lawsuit against Bristol-Myers Squibb and encourages investors with losses greater than $ 100,000 to contact the firm

LOS ANGELES, November 1, 2021 / PRNewswire / – Schall Law Firm, a National Shareholder Rights Litigation Firm, Announces the Filing of a Class Action Against Bristol-Myers Squibb Company (“Bristol-Myers” or “the Company”) (NYSE: BMY) on Behalf of Former Celgene Shareholders Corporation (“Celgene”) (Nasdaq: CELG) which received contingent value rights (“CVR”) (NYSE: BMY.RT) for violation of federal securities laws.

)” src=”https://s.yimg.com/ny/api/res/1.2/D_CNBB56Qe9xFtdISWhfkQ–/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5Nw–/https://s.yimg.com/uu/api/res/1.2/KMwozeHUBL5W2yKF483CXg–~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/cd1f8b01eb457a9d132a31cb464b61d6″ class=”caas-img”/>

(PRNewsfoto / Schall Law Firm)

Investors who have received CVRs in exchange for their shares in accordance with the Bristol-Myers Agreement $ 74 billion acquisition of Celgene on November 20, 2019 (“Merger”) are encouraged to contact the firm before December 6, 2021.

If you are a shareholder who has suffered a loss, Click here to participate.

We also encourage you to contact Brian schall Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email to [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by legal counsel. If you choose to do nothing, you can remain an absent member of the group.

According to the complaint, the company made false and misleading statements to the market. The joint power of attorney filed with the SEC in connection with the merger indicated that Celgene shareholders would receive CVRs exchangeable for $ 9.00 per action once the “milestones” have been reached. Bristol-Myers has taken steps to avoid paying CVR shareholders, including making flawed statements to the FDA to delay Liso-cel’s eventual approval, resulting in a missed milestone payment. Based on these facts, the Company’s public statements were false and misleading throughout the merger period. When the market learned the truth about Bristol-Myers, Celgene’s former shareholders suffered losses.

Join the case to recoup your losses.

Schall law firm represents investors around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered an attorney’s advertisement in certain jurisdictions under applicable law and rules of professional conduct.

CONTACT:

Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-action-notice-the-schall-law-firm-announces-the-filing-of-a-class-action-lawsuit-against-bristol-myers- squibb-company-and-encourage-investors-with-losses-exceeding-100-000-to-contact-the-firm-301412899.html

SOURCE Schall Law Firm


Source link

About the author